GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bio-Techne Corp (MEX:TECH) » Definitions » EV-to-FCF

Bio-Techne (MEX:TECH) EV-to-FCF : 60.96 (As of Sep. 27, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Bio-Techne EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Bio-Techne's Enterprise Value is MXN248,793 Mil. Bio-Techne's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2024 was MXN4,081 Mil. Therefore, Bio-Techne's EV-to-FCF for today is 60.96.

The historical rank and industry rank for Bio-Techne's EV-to-FCF or its related term are showing as below:

MEX:TECH' s EV-to-FCF Range Over the Past 10 Years
Min: 25.93   Med: 48.31   Max: 80.52
Current: 51.49

During the past 13 years, the highest EV-to-FCF of Bio-Techne was 80.52. The lowest was 25.93. And the median was 48.31.

MEX:TECH's EV-to-FCF is ranked worse than
79.5% of 400 companies
in the Biotechnology industry
Industry Median: 6.825 vs MEX:TECH: 51.49

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2024-09-27), Bio-Techne's stock price is MXN2418.75. Bio-Techne's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 was MXN18.035. Therefore, Bio-Techne's PE Ratio (TTM) for today is 134.11.


Bio-Techne EV-to-FCF Historical Data

The historical data trend for Bio-Techne's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bio-Techne EV-to-FCF Chart

Bio-Techne Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only 67.22 57.61 48.70 60.69 49.14

Bio-Techne Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 60.69 51.90 55.66 45.55 49.14

Competitive Comparison of Bio-Techne's EV-to-FCF

For the Biotechnology subindustry, Bio-Techne's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bio-Techne's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Bio-Techne's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Bio-Techne's EV-to-FCF falls into.



Bio-Techne EV-to-FCF Calculation

Bio-Techne's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=248793.157/4081.059
=60.96

Bio-Techne's current Enterprise Value is MXN248,793 Mil.
Bio-Techne's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN4,081 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Bio-Techne  (MEX:TECH) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Bio-Techne's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=2418.75/18.035
=134.11

Bio-Techne's share price for today is MXN2418.75.
Bio-Techne's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN18.035.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Bio-Techne EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Bio-Techne's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Bio-Techne Business Description

Traded in Other Exchanges
Address
614 McKinley Place N.E., Minneapolis, MN, USA, 55413
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.